NFKB1 and neoplasm: Diosgenin downregulates the MAPK, NF-κB, and Akt signaling pathways by inhibiting the phosphorylation of NF-κB/p65, JNK, IKK-β, Akt, and ERK, resulting in its anti-tumor effect.